The U.S. Food and Drug Administration (FDA) approved an expanded indication trial for low-risk surgical patients using Medtronic’s CoreValve Evolut R System transcatheter aortic valve replacement (TAVR) system. Patients with aortic stenosis, who are at a low surgical mortality risk as determined by a heart team, will be enrolled in the trial.
